CIT-013 is named as an intervention in 3 current clinical trials in our Netherlands, Germany, Spain, Poland, UK, Canada and Belgium registers. 2 are recruiting patients now. The most common phase is Phase 2. The lead sponsor is Citryll BV. The most-studied condition is Hidradenitis Suppurativa (HS).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study With CIT-013 in RA Patients
NCT06567470 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis
|
Phase 2 | Recruiting | Citryll BV | Germany, Spain, Netherlands, Belgium, Poland |
|
A Study With CIT-013 in HS Patients
NCT06993233 · ClinicalTrials.gov ↗ · Hidradenitis Suppurativa (HS)
|
Phase 2 | Recruiting | Citryll BV | UK, Germany, Spain, Netherlands, Poland, Canada |
|
Phase 1 Trial to Evaluate 150 mg Subcutaneous CIT-013
NCT07499908 · ClinicalTrials.gov ↗ · Healthy Adult
|
Phase 1 | Not yet open | Citryll BV | Netherlands |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Citryll BV | 3 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Netherlands | 3 | 2 |
| Clinical trials in Germany | 2 | 2 |
| Clinical trials in Spain | 2 | 2 |
| Clinical trials in Poland | 2 | 2 |
| Clinical trials in UK | 1 | 1 |
| Clinical trials in Canada | 1 | 1 |
| Clinical trials in Belgium | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our Netherlands, Germany, Spain, Poland, UK, Canada and Belgium registers name CIT-013 as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 2 with sites in Netherlands, 2 with sites in Germany, 2 with sites in Spain, 2 with sites in Poland, 1 with sites in UK, 1 with sites in Canada and 1 with sites in Belgium. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Citryll BV. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how CIT-013 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CIT-013 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CIT-013 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.